Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study

Table 2 Comparison between the Argatroban and the unfractionated heparin group: secondary endpoints: thrombosis, bleeding, transfusion, and cerebral pathologies

Variables	Argatroban n = 39	UFH n = 78	p value
Major thrombosis	11 (28)	13 (17)	0.145
Pulmonary embolism on ECMO	2 (5)	3 (4)	0.747
ECMO days per oxygenator	9 (6; 12)	8 (6; 10)	0.210
Major bleeding	27 (69)	63 (81)	0.163
RBC transfusion per day on ECMO	0.3 (0; 0.5)	0.3 (0; 0.7)	0.287
FFP transfusion per day on ECMO	0.0 (0; 0)	0.0 (0; 0)	0.063
Platelet transfusion/day on ECMO	0.0 (0; 0)	0.0 (0; 0.1)	0.044
Cerebral hemorrhage	2 (5)	8 (10)^a	0.584
Successful discharge from hospital	30 (77)	47 (60)	0.073
SOFA score at the end of ECMO support	6.0 (4; 8)	5.0 (3; 7)	0.058

Data are expressed as n (%), median (25. percentile; 75. percentile); UFH: unfractionated heparin group; major: thrombosis due to vein occlusion > 50%; major bleeding: drop in hemoglobin of ≥ 2 g/dl/day, and/or transfusion of ≥ 2 packed red cells/24 h, retroperitoneal, cerebral, or pulmonary bleeding; RBC: red blood cell; FFP: fresh frozen plasma
^aOne patient additionally suffered from cerebral ischemia; significant p values (p < 0.05) are marked in bold

ISSN: 1364-8535